Journal of Clinical Oncology
Articles in this Issue
The association of androgen deprivation therapy with time to dementia: A large competing risk analysis.
136 Background: Androgen deprivation therapy (ADT), used for advanced prostate cancer (PC), has shown mixed associations w...
Induction ipilimumab plus nivolumab followed by consolidating chemoradiotherapy as bladder-sparing treatment in stage II/III urothelial carcinoma of the bladder: The phase 2 Indi-Blade trial.
LBA637 Background: Radical cystectomy remains the most commonly used curative treatment for muscle-invasive bladder cancer...
Prognostic significance of the preoperative De Ritis ratio and its association with sarcopenia in muscle-invasive bladder cancer: A multicenter retrospective study.
859 Background: The De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) has been reported as a prognostic...
Comparing concordance of prostate cancer clinical trials and disease incidence in the United States in 2021 and 2022.
335 Background: Prostate cancer is the second-leading cause of cancer-related death in men in the United States. However,...
The nature of progression on active surveillance for grade group 2 prostate cancer.
330 Background: Active surveillance (AS) is included in guidelines as a management option for men with Gleason Grade Group...
Novel androgen receptor inhibitors for the treatment of metastatic castration-sensitive prostate cancer: A cost-effectiveness analysis.
196 Background: Management of metastatic castration-sensitive prostate cancer (mCSPC) continues to evolve. Pivotal trials...
Impact of lutetium Lu 177 vipivotide tetraxetan on prostate cancer outcomes by race.
155 Background: Lutetium Lu-177 vipivotide tetraxetan (Pluvicto) is a PSMA-targeted radioligand therapy approved for men w...
Primary retroperitoneal lymph node dissection for clinical stage IIA/B metastatic seminoma: A multi-centre Australian experience.
601 Background: Seminoma is highly chemo-sensitive and radio-sensitive. Contemporary guidelines describe chemotherapy and...
Membranous and cytoplasmic Nectin4 expression and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
801 Background: Enfortumab vedotin plus pembrolizumab (EV/P) is the standard therapy for metastatic urothelial carcinoma (...
3-weekly docetaxel 75 mg/m <sup>2</sup> vs 2-weekly docetaxel 50 mg/m <sup>2</sup> in combination with darolutamide + ADT in patients with mHSPC: Subgroup analyses from the randomised phase 3 ARASAFE trial.
153 Background: Triple therapy with androgen deprivation therapy (ADT), darolutamide (DARO), and docetaxel (DOCE) is appro...
Blood- and urine-based ctDNA profiling and monitoring in bladder carcinoma in situ.
846 Background: Carcinoma in situ (CIS) of the bladder is a high-grade, flat urothelial carcinoma with significant risk of...
Metaproteomics based subtypes in muscle invasive bladder carcinoma and association with survival.
812 Background: Muscle-invasive bladder carcinoma (MIBC) is associated with high recurrence and mortality rates, and curre...
Neoadjuvant chemotherapy of node-positive M0 urothelial bladder cancer.
684 Background: Patients (pts) with muscle-invasive bladder cancer (MIBC) who are initially candidates for radical cystect...
Micro-ultrasound compared with MRI-targeted biopsy in detecting clinically significant prostate cancer: Systematic review and meta-analysis.
318 Background: Prostate cancer is highly prevalent, and diagnostic pathways must maximize detection of clinically signifi...
Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON.
167 Background: Darolutamide (DARO), an androgen receptor inhibitor (ARI), demonstrates low blood–brain barrier penetratio...
Comparative risk of medication-related osteonecrosis of the jaw and survival outcomes with RANKL inhibitors versus bisphosphonates in metastatic prostate cancer.
60 Background: Bone-modifying agents (BMAs) are standard in metastatic prostate cancer, preventing skeletal complications...
Hemoglobin, albumin, lymphocyte, and platelet (HALP) score as a prognostic indicator in patients with bladder cancer undergoing radical cystectomy.
852 Background: Prognosis in cancer patients is a combination of tumor characteristics and immunobiology. While a variety...
Mechanistic insights into bacillus Calmette-Guérin (BCG) sensitivity in non-muscle invasive bladder cancer (NMIBC) with ERCC2 alterations.
813 Background: Alterations in the nucleotide excision repair (NER) gene ERCC2 are...
Risk factors and treatment outcomes in metastatic prostate cancer with brain metastases.
62 Background: Prostate cancer with brain metastases (PCBM) are rare and carry poor prognosis. While prior studies suggest...
Association of HER2 and NECTIN4 expression with clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).
796 Background: NECTIN4 and HER2 immunohistochemistry (IHC) expression are emerging biomarkers and targets of approved the...
Real-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.
476 Background: Lack of standardized reporting and collection of patient-reported outcomes (PROs) limits cross-trial compa...
Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC).
TPS295 Background: Prostate cancer harbors an immunosuppressive tumor microenvironment (TME), with few effector T cells an...
Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
525 Background: Consolidative nephrectomy (CN) is undertaken in selected patients with metastatic renal cell carcinoma (mR...
Unveiling the rare: p16 expression and real-world management of penile cancer in Bolivia—Insights from a country with high HPV and penile cancer prevalence.
6 Background: Penile squamous cell carcinoma (PSCC) is rare but a major challenge in regions with high human papillomaviru...
Efficacy and safety of disitamab vedotin combined with intravesical electromotive mitomycin-C in patients with HER2-expressing high-risk non–muscle-invasive bladder cancer: A phase II study.
772 Background: HER2 expression is an independent predictor of poor response to Bacillus Calmette–Guérin (BCG) therapy. Di...